Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928510 · ClinicalTrials.gov registry record
Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- 1
- Enrollment target
NCT02928510: Clinical Trial study, sponsored by Jonsson Comprehensive Cancer Center.
NCT02928510 is a clinical trial that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02928510 was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some patients. Studying stool, blood, and tissue samples in the lab from patients who are given idelalisib may help doctors learn more about the side effects and may help to treat them in future patients.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Colonoscopy
- OTHER Laboratory Biomarker Analysis
- DRUG Idelalisib
- PROCEDURE Colposcopic Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2018-06-05 |
Why NCT02928510 stopped before completion
NCT02928510 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02928510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02928510 about?
NCT02928510 is a clinical study titled "Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma". This research trial studies the mechanisms of idelalisib-associated diarrhea in patients with chronic lymphocytic leukemia, indolent non-hodgkin lymphoma, or small lymphocytic lymphoma that has come back after a period of improvement. The cancer treatment drug idelalisib triggers diarrhea in some pa...
What is the current status of trial NCT02928510?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2016-02-01. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT02928510?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Colonoscopy (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Idelalisib (DRUG), Colposcopic Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02928510?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI